Valion Bio, Inc. Common Stock (NASDAQ:VBIO) Short Interest Up 73.8% in June

Posted by Donald Scott on Jul 4th, 2026

Valion Bio, Inc. Common Stock (NASDAQ:VBIO – Get Free Report) saw a large growth in short interest in June. As of June 15th, there was short interest totaling 260,360 shares, a growth of 73.8% from the May 31st total of 149,795 shares. Based on an average daily volume of 693,061 shares, the days-to-cover ratio is presently 0.4 days. Currently, 8.3% of the shares of the company are short sold.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Valion Bio, Inc. Common Stock in a research note on Monday, April 20th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Valion Bio, Inc. Common Stock currently has an average rating of “Sell”.

View Our Latest Stock Report on VBIO

Valion Bio, Inc. Common Stock Price Performance

Shares of NASDAQ VBIO opened at $0.50 on Friday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.02 and a current ratio of 3.31. Valion Bio, Inc. Common Stock has a one year low of $0.46 and a one year high of $5.60. The firm has a market capitalization of $1.60 million, a P/E ratio of -0.07 and a beta of 1.82. The company’s fifty day moving average is $0.80 and its two-hundred day moving average is $1.02.

Valion Bio, Inc. Common Stock (NASDAQ:VBIO – Get Free Report) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($2.23) earnings per share (EPS) for the quarter.

Valion Bio, Inc. Common Stock Company Profile

(Get Free Report)

Tivic Health Systems is a commercial-stage medical technology company that develops and markets non-drug, neuromodulation-based therapies for nasal and sinus health. The company’s solutions are designed to alleviate sinus pain, pressure and congestion through gentle microcurrent and vibration stimulation. By targeting the underlying nerve pathways in the nasal passages, Tivic Health aims to provide an alternative to over-the-counter and prescription medications without introducing systemic side effects.

The flagship product, ClearUP™ Sinus Pain Relief, is an FDA-cleared, hand-held device intended for home use.